학술논문

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report.
Document Type
Article
Source
JCO Precision Oncology. 4/20/2023, Vol. 7, p1-5. 5p.
Subject
*PROTEIN-tyrosine kinase inhibitors
*ADENOCARCINOMA
*CIRCULATING tumor DNA
Language
ISSN
2473-4284
Abstract
Sequential tyrosine kinase inhibitor treatment and ctDNA monitoring is feasible in ROS1-positive PDAC—a histology agnostic paradigm. [ABSTRACT FROM AUTHOR]